Insmed Incorporated (INSM) Expected to Announce Quarterly Sales of $2.68 Million

Share on StockTwits

Brokerages expect Insmed Incorporated (NASDAQ:INSM) to report $2.68 million in sales for the current quarter, according to Zacks Investment Research. Three analysts have issued estimates for Insmed’s earnings. The lowest sales estimate is $2.20 million and the highest is $3.04 million. The business is expected to announce its next earnings report on Friday, February 22nd.

On average, analysts expect that Insmed will report full year sales of $2.24 million for the current fiscal year, with estimates ranging from $910,000.00 to $3.04 million. For the next year, analysts expect that the firm will report sales of $42.28 million, with estimates ranging from $36.70 million to $52.73 million. Zacks Investment Research’s sales averages are an average based on a survey of research firms that follow Insmed.

Insmed (NASDAQ:INSM) last issued its quarterly earnings results on Tuesday, October 30th. The biopharmaceutical company reported ($1.14) EPS for the quarter, missing the Zacks’ consensus estimate of ($1.06) by ($0.08).

A number of research analysts recently commented on INSM shares. HC Wainwright restated a “buy” rating and issued a $43.00 price target on shares of Insmed in a research report on Friday, August 3rd. ValuEngine cut Insmed from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, September 4th. Credit Suisse Group upped their price target on Insmed from $33.00 to $35.00 and gave the company a “buy” rating in a research report on Monday, October 1st. Goldman Sachs Group set a $25.00 price target on Insmed and gave the company a “hold” rating in a research report on Wednesday, September 19th. Finally, Zacks Investment Research raised Insmed from a “sell” rating to a “hold” rating in a research report on Thursday, August 9th. Four analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus price target of $35.50.

Shares of NASDAQ INSM traded down $0.16 during mid-day trading on Friday, reaching $16.62. The company had a trading volume of 15,033 shares, compared to its average volume of 836,525. The company has a debt-to-equity ratio of 1.07, a quick ratio of 10.06 and a current ratio of 10.06. Insmed has a one year low of $13.85 and a one year high of $33.94. The stock has a market capitalization of $1.26 billion, a P/E ratio of -5.85 and a beta of 1.73.

In other news, Director Steinar J. Engelsen purchased 16,085 shares of the company’s stock in a transaction dated Thursday, November 1st. The shares were purchased at an average price of $15.79 per share, with a total value of $253,982.15. The purchase was disclosed in a filing with the SEC, which is available through this hyperlink. Also, CEO William Lewis acquired 15,700 shares of the firm’s stock in a transaction that occurred on Thursday, November 1st. The shares were bought at an average price of $15.90 per share, for a total transaction of $249,630.00. Following the completion of the purchase, the chief executive officer now owns 151,247 shares in the company, valued at approximately $2,404,827.30. The disclosure for this purchase can be found here. Insiders have bought a total of 34,785 shares of company stock worth $551,522 in the last ninety days. Insiders own 3.88% of the company’s stock.

Several large investors have recently added to or reduced their stakes in INSM. Voya Investment Management LLC raised its stake in shares of Insmed by 31.9% during the 2nd quarter. Voya Investment Management LLC now owns 1,053,468 shares of the biopharmaceutical company’s stock valued at $24,914,000 after purchasing an additional 254,853 shares during the period. JPMorgan Chase & Co. lifted its position in Insmed by 91.5% during the third quarter. JPMorgan Chase & Co. now owns 506,391 shares of the biopharmaceutical company’s stock valued at $10,240,000 after purchasing an additional 241,921 shares in the last quarter. Emerald Mutual Fund Advisers Trust lifted its position in Insmed by 34.2% during the third quarter. Emerald Mutual Fund Advisers Trust now owns 845,858 shares of the biopharmaceutical company’s stock valued at $17,103,000 after purchasing an additional 215,743 shares in the last quarter. American Century Companies Inc. purchased a new position in Insmed during the second quarter valued at $3,030,000. Finally, Bellevue Group AG lifted its position in Insmed by 26.8% during the second quarter. Bellevue Group AG now owns 424,051 shares of the biopharmaceutical company’s stock valued at $10,029,000 after purchasing an additional 89,562 shares in the last quarter.

About Insmed

Insmed Incorporated, a biopharmaceutical company, focuses on the development and commercialization of therapies for patients with rare diseases. The company's lead product candidate is amikacin liposome inhalation suspension, which is in late-state development for adult patients with treatment refractory nontuberculous mycobacteria lung disease caused by mycobacterium avium complex.

Recommended Story: Cost of Debt

Get a free copy of the Zacks research report on Insmed (INSM)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Insmed (NASDAQ:INSM)

Receive News & Ratings for Insmed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insmed and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply